InnoCan Pharma Corporation
INNO
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 87.09% | 85.69% | 164.81% | -39.13% | 26.84% |
| Total Depreciation and Amortization | -25.00% | 0.00% | 11.11% | 42.86% | -38.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -210.49% | -69.14% | -92.02% | 1,052.85% | -355.36% |
| Change in Net Operating Assets | 116.38% | -924.78% | 186.30% | -1,754.55% | -29.65% |
| Cash from Operations | 61.56% | -39.69% | 194.67% | 35.71% | 3.89% |
| Capital Expenditure | 55.56% | -- | 70.00% | 92.59% | 18.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Investing | 822.22% | 81.25% | 66.67% | 94.12% | 43.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -20.00% | -20.00% | 16.67% | 16.67% | -150.00% |
| Issuance of Common Stock | -- | -48.16% | -- | 196.17% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.86% | -31.98% | -- | 442.86% | -- |
| Cash from Financing | -64.22% | -40.68% | 16.67% | 306.16% | 56,000.00% |
| Foreign Exchange rate Adjustments | -115.87% | 138.30% | -708.33% | 147.37% | 172.41% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 64.75% | -120.28% | 182.96% | 182.75% | 90.54% |